By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
It has been a mixed year for EyePoint Pharmaceuticals, Inc. insiders: $72,000 bought by two people and $2 million sold by three, so more selling than buying overall.
Biggest single buyer: Zaderej Karen L., Director, with roughly $52,000. Notably, at least one C-suite executive was among the buyers.
On the institutional side, 189 funds reported holding EYPT at the end of Q2 2026, and funds were split between buying and selling. Last full quarter: net buying by insiders. Insiders bought in 3 of the last 7 full quarters.
Are insiders buying or selling EYPT stock?
In the last 12 months EyePoint Pharmaceuticals, Inc. insiders made open-market purchases worth about $72,000 and sales worth about $2 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in EYPT?
The most recent open-market insider trade in EYPT was filed on 2026-08-18.
How many institutions own EYPT?
189 investment managers reported holding EYPT in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded EYPT?
No congressional trades in EYPT were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).